Evidence map›Paper›PMID 38576993›Full record

ArticleAnnals of medicine and surgery (2012)2024

Seroprevalence of brucellosis antibodies and associated risk factors among the hospitalized patient, Aleppo, Syria: a hospital-based cross-sectional study.

Mohammed Abdulrazzak, Mohammed Moutaz Alshaghel, Rami Anadani, Muhammad Besher Shabouk, Moustafa Alhashemi, Fatima Breim, Khaled Ali Alahmad, Mohammed Alabrash, Samer Haj Kadour

Abstract read
In one paragraph

Article in Annals of medicine and surgery (2012), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Reemergence of Brucella abortus, Israel, 2021.Emerging infectious diseases · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohammed AbdulrazzakFaculty of Medicine.
Mohammed Moutaz AlshaghelFaculty of Medicine.
Rami AnadaniFaculty of Medicine.
Muhammad Besher ShaboukFaculty of Medicine.
Moustafa AlhashemiFaculty of Medicine.
Fatima BreimFaculty of Medicine.
Khaled Ali AlahmadFaculty of Medicine.
Mohammed AlabrashFaculty of Medicine.
Samer Haj KadourDepartment of Laboratory, Aleppo University Hospital, Aleppo, Syria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction and importance: Brucellosis is one of the most common infectious diseases in the world, especially in developing countries. Recent reports show that Syria is among the top ten countries where brucellosis is most prevalent. The purpose of this study is to estimate the seroprevalence of brucellosis antibodies among the hospitalized patients, in one of the largest hospitals in northern Syria. Materials and methods: A cross-sectional study was conducted among the hospitalized patients. The authors used a questionnaire to collect sociodemographic and brucellosis-related data from the patients. The authors also collected blood samples from these patients to be screened for brucellosis antibodies using Wright Coombs Agglutination and 2-mercaptoethanol tests, during the period from November 2021 and March 2022. Results: Among the 776 patients who were recruited in the study, the seroprevalence of brucellosis antibodies was 13.1% ( Conclusion: This study is the first to describe the epidemiology of brucellosis in northern Syria. It clearly shows high rates of positivity, which reflects immense challenges facing the public health sector in Syria. The best next step in light of this crisis is to raise awareness among population about brucellosis and its risk factor.

Indexed as

2-MercaptoethanolAleppobrucellosisseroprevalenceSyriaWright test

Identifiers

PMID38576993
PMCPMC10990308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.